Dear Customer: GlaxoSmithKline is recalling the Ventolin HFA Inhaler lots listed below from the retail level. These lots are being recalled due to the potential that a very low level of canisters may not contain sufficient propellant to deliver the labeled claim of 60 actuations. Patients requiring treatment for increased symptoms of bronchospasm (i.e. shortness of breath, wheezing, chest tightness) but not receiving medication could potentially need to seek additional medical help. Product Description
Ventolin HFA Inhaler Sample - 60 Actuations
Ventolin HFA Inhaler Sample - 60 Actuations
Ventolin HFA Inhaler Sample - 60 Actuations
Ventolin HFA Inhaler Sample - 60 Actuations
Ventolin HFA Inhaler Sample - 60 Actuations
Ventolin HFA Inhaler Institutional Pack – 60 Actuations 0173-0682-24 1ZP0856 Ventolin HFA Inhaler Institutional Pack – 60 Actuations 0173-0682-24 1ZP1981 Ventolin HFA Inhaler Institutional Pack – 60 Actuations 0173-0682-24 1ZP6941 Ventolin HFA Inhaler Institutional Pack – 60 Actuations 0173-0682-24 1ZP7824 Ventolin HFA Inhaler Institutional Pack – 60 Actuations 0173-0682-24 1ZP9063 Ventolin HFA NOVAPLUS – 60 Actuations
Recalled product was shipped between September 23, 2011 and January 10, 2012.
Stop distributing and immediately quarantine all listed Ventolin HFA Inhaler lots. Please pick up all remaining inventory at the pharmacy level and provide the corresponding credit. Please carry out a physical count and record this data on the business reply form and the packing slip which are included with this letter and send it to GSK PR Customer Service Department at 787-774-1719. Please examine your inventory immediately and return all units ofthe listed Ventolin HFA Inhaler lots to GlaxoSmithKline Puerto Rico. It is very important that you complete the requested information on the enclosed Business Reply Form and return it to us within five (5) business days, even if you do not have the listed Ventolin HFA Inhaler lots in stock.
Thank you for your cooperation. For shipping assistance or questions about the withdrawal process, please contact GSK PR, Customer Service Department at 787-774-1600 extensions 4991, 4990 and 2068. Reimbursement will be issued at current WAC price. These special instructions apply to GSK PR Customers. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. We appreciate your immediate attention and cooperation. GlaxoSmithKline remains committed to product quality, integrity, and patient satisfaction and we sincerely regret any inconvenience this action may cause.
Wohnungs- und Siedlungsgesellschaft Kärnten GmbH. Neubau von 2 Wohnhäusern mit je 9 Wohneinheiten in der Gemeinde Brückl MALEREI: BAUWEISE: Stiegenhaus: Weiße scheuerbeständige Innendispersion Fundamente: Plattenfundament in Stahlbeton lt. Statik Außenwände: Mantelbetonwände 25 cm mit 16 cm starken FENSTER: Kunststofffenster weiß, mit Isolierverglasung I
DEA Describes Policy On he is able to provide himself with the medicine in question in Importing Controlled Drugs the country of destination. In view of the express provisionthat each Party (i.e. the countries of transit and destination)is entitled to satisfy itself that the preparations have been The following is a portion of a policy statement made by lawfully obtained, it would be use